Sold as Cypsedo. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Cipepofol (sold as Cypsedo), first approved May 29, 2026, with 0 new uses approved and 0 published complete response letters.
| HSK3486 (Cipepofol) Injectable Emulsion for Induction of General Anesthesia in Pediatric Subjects Undergoing Elective SurgeryGeneral Anesthetic · Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Apr 6, 2026 |
| Population Pharmacokinetics and Pharmacodynamics of CiprofolHip Fractures (ICD-10 72.01-72.2), Osteoarthritis, Knee and Hip · Shanghai Geriatric Medical Center | — | Recruiting | Dec 24, 2025 |
| A Study to Evaluate the Accuracy of aTCI Model of Cipepofol in Patients With General Anesthesia During Elective SurgeryAnesthesia · Haisco Pharmaceutical Group Co., Ltd. | Phase 4 | Recruiting | Dec 18, 2024 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
